Therapy News and Research

RSS

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.

7 Oct 2009

Repros announces results of its Androxal efficacy study for secondary hypogonadism

Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.

7 Oct 2009

Diuretics effective as second-line agents in treating high blood pressure

A new review shows that diuretics — drugs often recommended as a first-line treatment for high blood pressure — are also effective when added as a second agent to other blood-pressure lowering drugs.

7 Oct 2009

HRT may increase urinary incontinence in postmenopausal women

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence.

7 Oct 2009

Jobless individuals are four times as likely as employed to report depression

A new national survey shows the economic downturn is taking a toll on the mental health of Americans. Individuals who are unemployed are four times as likely as those with jobs to report symptoms consistent with severe mental illness.

7 Oct 2009

NIH awards NeoStem a GO grant to investigate the potential of stem cells in regenerating bone

NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need and holder of the exclusive, worldwide license to VSEL(TM) Technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that it has been awarded a grant of $108,746 for the repair of bone defects by human stem cells under the American Recovery and Reinvestment Act (RRA) of 2009 from the National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) of the National Institutes of Health (NIH).

7 Oct 2009

Aerobic and strength training exercises safe and effective for rheumatoid arthritis patients

Exercise programs designed to improve strength and stamina are safe and effective treatments for rheumatoid arthritis (RA), according to a new Cochrane Systematic Review.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Uroplasty, Inc., a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today highlighted presentations, workshops and posters focused on its products at the 39th Annual Meeting of the International Continence Society Meeting (ICS), September 29 - October 3 in San Francisco.

7 Oct 2009

Cognitive behavioral therapy effective for bulimia and binge eating disorders

Although most people with bulimia and binge eating disorders wait many years before seeking help, a new review shows that psychological treatment can make a large difference — and that cognitive behavioral therapy (CBT) is the most effective talk therapy for these disorders.

6 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

Chattem announces financial results for the nine months and third fiscal quarter ended August 31, 2009

Chattem, Inc., a leading marketer and manufacturer of branded consumer products, today announced financial results for the nine months and third fiscal quarter ended August 31, 2009.

6 Oct 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be safe and well tolerated.

6 Oct 2009

Triage NGAL Test allows early identification of AKI in ICU patients

According to a new study now available online, and to be published in an upcoming issue of the Journal of Critical Care, bedside testing for a blood biomarker called neutrophil gelatinase-associated lipocalin (NGAL) in patients being admitted to the intensive care unit can help to identify patients at risk for acute kidney injury (AKI).

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

Ventilation mask leakage may contaminate hospital setting

New research shows that certain noninvasive positive pressure ventilation (NPPV) masks may leak exhaled air up to a distance of 1 m from patients receiving treatments.

6 Oct 2009

AAAHC accreditation for Laser Spine Institute Tampa

Laser Spine Institute, leaders in minimally invasive spinal surgery, is pleased to announce the accreditation of LSI Tampa by the Accreditation Association for Ambulatory Health Care.

6 Oct 2009

Telephone program to mange depression offers significant benefits at moderate increase in costs: Study

Patients who participate in a structured telephone program to manage their depression appear to experience significant benefits and only a moderate increase in health care costs when compared with those who receive usual care, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

6 Oct 2009

Emergency Ultrasound Consultants, TSG collaborate to reduce medical errors

Emergency Ultrasound Consultants, LLC (EUC), the experts in point-of-care ultrasound education and quality assurance solutions, announced today a strategic partnership with The Sullivan Group (TSG), a world leading provider of patient safety, risk management and performance improvement solutions for healthcare professionals.

6 Oct 2009

Gene therapy to improve ailing heart's contractions of muscle cells

Scientists from the Universities of Michigan and Minnesota show in a research report published online in the FASEB Journal (http://www.fasebj.org) that gene therapy may be used to improve an ailing heart's ability to contract properly. In addition to showing gene therapy's potential for reversing the course of heart failure, it also offers a tantalizing glimpse of a day when "closed heart surgery" via gene therapy is as commonly prescribed as today's cocktail of drugs.

6 Oct 2009

Therapy News and Research

Stereotactic Radiosurgery for metastatic brain tumors reduces risks of learning and memory problems

Repros announces results of its Androxal efficacy study for secondary hypogonadism

Diuretics effective as second-line agents in treating high blood pressure

HRT may increase urinary incontinence in postmenopausal women

Jobless individuals are four times as likely as employed to report depression

NIH awards NeoStem a GO grant to investigate the potential of stem cells in regenerating bone

Aerobic and strength training exercises safe and effective for rheumatoid arthritis patients

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Cognitive behavioral therapy effective for bulimia and binge eating disorders

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

Chattem announces financial results for the nine months and third fiscal quarter ended August 31, 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Triage NGAL Test allows early identification of AKI in ICU patients

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

Ventilation mask leakage may contaminate hospital setting

AAAHC accreditation for Laser Spine Institute Tampa

Telephone program to mange depression offers significant benefits at moderate increase in costs: Study

Emergency Ultrasound Consultants, TSG collaborate to reduce medical errors

Gene therapy to improve ailing heart's contractions of muscle cells

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News